CAPhO Oncology Fundamentals Day Saturday, October 1, 2016
CAPhO Oncology Fundamentals Day
Saturday, October 1, 2016
Page | 2 #OFD16 www.capho.org
Accreditation
CAPhO Oncology Fundamentals Day is accredited by the Canadian Council on
Continuing Education in Pharmacy (CCCEP) for 6.67 continuing education credits
(CEUs). Participation on October 1st is required to receive a letter of participation.
CCCEP Number: 1152-2016-1830-C-P
Program at a Glance
Click on the session title or presenter name to go directly to the session description or presenter
biography.
Note: All times indicated are Eastern Daylight Times (EDT).The program below is subject to change.
Time
Session
09:30 – 09:40
Welcome Remarks
09:40 – 11:50
Fundamentals of Hematologic Cancer
09:40 – 10:20
Lymphoma - Kyla Marien, Tom Baker Cancer Clinic, Calgary, AB
10:25 – 11:05
Chronic Leukemias - Danica Wasney, CancerCare Manitoba, Winnipeg, MB
11:10 – 11:50
Multiple Myeloma - Tina Crosbie, The Ottawa Hospital, Ottawa, ON
11:50 – 12:30
Break
12:30 – 14:55
Fundamentals of Solid Tumours
12:30 – 13:15
Breast Cancer - Melanie Danilak, Alberta Health Services, Edmonton, AB
13:20 – 14:05
Colorectal Cancer - Tom McFarlane, University of Waterloo, Kitchener, ON
14:10 – 14:55
Lung Cancer - Jason Wentzell, The Ottawa Hospital, Ottawa, ON
14:55 – 15:20
Break
15:20 – 18:00
Chemotherapy Toxicity Management
15:20 – 16:00
Chemotherapy Induced Nausea and Vomiting - Sally Waignein, BC Cancer
Agency, Vancouver, BC
16:05 – 16:45
Other Gastro-Intestinal Toxicities - Glenn Myers, Horizon Health Network,
Moncton, NB
16:50 – 17:20
Febrile Neutropenia - Tara Leslie, Tom Baker Cancer Centre/University of
Alberta, Calgary, AB
17:25 – 18:00
Skin, Nail and Hair Toxicities – Lynn Hartery, Eastern Health, St. John’s, NL
18:00 – 18:10
Closing Remarks
CAPhO Oncology Fundamentals Day
Saturday, October 1, 2016
Page | 3 #OFD16 www.capho.org
Session Descriptions and Presenter Biographies
Fundamentals of Hematologic Cancers
Lymphoma - Kyla Marien, Tom Baker Cancer Clinic, Calgary, AB
Lymphomas are a heterogeneous group of over 40 different malignancies originating from T
cells and B cells in the lymphatic system. Within this group of diseases there are similarities
and differences within the pathophysiology, natural history, and prognosis. As treatment
options differ dependent on the specific disease, the adverse effects patients experience can
be diverse. Pharmacists are well positioned to assist in monitoring lymphoma patients for
therapy toxicities and optimizing supportive care measures.
Learning Objectives:
1. Appreciate the numerous types of lymphoma and gain understanding in the
differences between Hodgkin and Non-Hodgkin, indolent and aggressive, and B-
cell versus T-cell lymphoma;
2. Discuss the incidence, pathophysiology, typical presentation, and prognostic
factors for lymphomas;
3. Describe some common treatment regimens, associated side effects, and
monitoring parameters for common types of lymphoma; and
4. Explore the role of CD20 monoclonal antibodies in lymphoma and discuss the
associated supportive care requirements.
Kyla Marien graduated from University of Saskatchewan in 2003
and currently works for Alberta Health Services at the Tom Baker
Cancer Centre as clinical hematology pharmacist. Over the past 13
years she has practiced in many diverse settings, including
community, geriatrics, hospital outpatient, and oncology. Kyla truly
believes each setting provided her with different skills and
knowledge to allow her to practice today in oncology with an
appreciation for a patient’s experiences both in the center and in
the community. Before joining the hematology clinical pharmacy team, Kyla developed her
oncology clinical skills with the oral chemotherapy management clinic. Kyla is a proud
CAPhO member.
CAPhO Oncology Fundamentals Day
Saturday, October 1, 2016
Page | 4 #OFD16 www.capho.org
Chronic Leukemias - Danica Wasney, CancerCare Manitoba, Winnipeg, MB
Systemic therapy for both Chronic Lymphocytic Leukemia (CLL) and Chronic Myelogenous
Leukemia (CML) has evolved significantly over the past 10-15 years. Systemic therapy for
both CLL and CML is complex due to both the regimens used and the patient populations,
as patients often present with comorbidities and multiple medications. Pharmacists are well
equipped to optimize clinical outcomes for patients with CLL and CML through education,
monitoring, symptom management, and medication management.
For CLL, selection of systemic therapy is based on a variety of patient and disease factors,
including staging, patient performance/functional status, and genetic markers. Systemic
therapy regimens for CLL are complex, consisting of both oral and parenteral anticancer
agents in addition to crucial supportive care agents. In addition, these regimens require
careful attention with regards to drug interactions and medication adherence. Pharmacists
can play a key role in optimizing care for patients with CLL.
For CML, the introduction of targeted therapies has resulted in significant advances in
patient survival and outcomes. Treatment selection is based on a variety of patient and
disease factors, including CML phase, patient performance/functional status, and genetic
markers. Since systemic therapies used to manage CML are usually orally administered on
an outpatient basis, pharmacists are positioned to support patients with CML through
management of drug interactions, symptom management, and medication adherence.
Learning Objectives:
After this presentation, participants should be able to:
1. Discuss the incidence, prevalence, pathophysiology, and staging for Chronic
Lymphocytic Leukemia (CLL);
2. Discuss the incidence, prevalence, pathophysiology, and staging (phases) for
Chronic Myelogenous Leukemia (CML);
3. Describe systemic treatment selection, monitoring parameters, and expected
outcomes for patients with CLL and CML; and
4. Explain common supportive care issues for patients with CLL and CML.
Danica Wasney is a Clinical Pharmacist for the Provincial Oncology
Drug Program at CancerCare Manitoba. In this role, she participates
in the provincial oncology drug review process including the
management of the provincial oncology drug formulary. She is a
member of the Expert Review Committee for the pan-Canadian
Oncology Drug Review (pCODR) at the Canadian Agency for Drugs
and Technologies in Health (CADTH).
Danica has clinical experience in breast, colorectal, thoracic and gynecologic cancers,
neuro-oncology, and hematologic malignancies.
CAPhO Oncology Fundamentals Day
Saturday, October 1, 2016
Page | 5 #OFD16 www.capho.org
Danica graduated from the Faculty of Pharmacy at University of Manitoba and completed an
Accredited Hospital Pharmacy Residency at The Ottawa Hospital. She is a Board Certified
Oncology Pharmacist, a member of the CAPhO Research Committee, and a past member of
the CAPhO Education Committee.
6
7
8
9
10
11
12
13
1
/
13
100%
